Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease

Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease

Children with very early onset inflammatory bowel disease (VEO‐IBD) may respond differently to coronavirus disease 2019 (COVID‐19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO‐IBD 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pediatric gastroenterology and nutrition 2024-04, Vol.78 (4), p.871-877
Hauptverfasser: Kastl, Arthur J., Weaver, Kimberly N., Zhang, Xian, Strople, Jennifer A., Adler, Jeremy, Kelsen, Judith R., Dubinsky, Marla C., Bousvaros, Athos, Watkins, Runa, Dai, Colin, Cross, Raymond K., Higgins, Peter D. R., Ungaro, Ryan, Bewtra, Meenakshi, Bellaguarda, Emanuelle A., Farraye, Francis A., Chun, Kelly, Zikry, Michael, Bastidas, Monique, Boccieri, Margie E., Firestine, Ann, Long, Millie D., Kappelman, Michael D.
Format: Artikel
Sprache:eng
Schlagworte:
antibody
COVID‐19
Moderna
Pfizer
vaccine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Children with very early onset inflammatory bowel disease (VEO‐IBD) may respond differently to coronavirus disease 2019 (COVID‐19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO‐IBD 
ISSN:0277-2116
1536-4801
DOI:10.1002/jpn3.12142